Barbie Doll Drug

(redirected from Afamelanotide)
A synthetic alpha melanocyte stimulating hormone (a-MSH) being developed by Clinuvel, for skin implantion or injection, which stimulates melanocytess to produce more (protective) melanin
References in periodicals archive ?
A randomized study conducted at two academic medical centers found that the combination of afamelanotide implant and narrow-band UVB phototherapy resulted in superior and faster repigmentation, compared with narrow-band UVB alone (JAMA Dermatol.
Current research is on Afamelanotide which is in phase II and III clinical trials and promising Melanocyte transplantation.
GOTHENBURG, SWEDEN -- A resorbable subcutaneous implant of afamelanotide significantly reduced painful phototoxic attacks in patients with erythropoietic protoporphyria in a year-long multinational clinical trial.
SCENESSE (R) is a first-in-class therapeutic being developed by Clinuvel, with the generic name (or INN) afamelanotide.
Known as Afamelanotide, it prevents the disease in fair-skinned people and lasts for two months, and avoids recurrence.
Following my article "Why bronzing jabs give me the needle" of February 6, 2009, which stated that Melanotan (an injectable unregulated drug which is bought over the internet by people hoping to improve their tan) contains afamelanotide, I have been asked by the Australian company Clinuvel, which develops afamelanotide, to make clear that afamelanotide is a drug being clinically tested on patients suffering from various skin disorders including cancer and is unrelated to the illegal and untested chemical substances offered by online vendors under the unofficial name "Melanotan I and II".
Afamelanotide reduces the number and severity of phototoxic reactions, shortens recovery time, and markedly improves disease-related quality of life in adults who have erythropoietic protoporphyria, according to a report in the New England Journal of Medicine.
SCENESSE (R) controls the release of its active ingredient, afamelanotide (16mg), in picogram concentration, one trillionth of a gram.
BAAR, Switzerland & MELBOURNE, Australia -- Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY), a global biopharmaceutical company with unique expertise on the interaction of light and human skin, today announced positive results of its first US Phase II study of the novel photoprotective drug afamelanotide, known as SCENESSE[R].
3 November 2011 - Australia-based biopharmaceutical company Clinuvel Pharmaceuticals Limited (ASX:CUV) unveiled on Thursday positive results of its first Phase II US study of its photoprotective drug afamelanotide, known as SCENESSE.
SurModics' biodegradable polymer drug delivery technology permits afamelanotide to be released in a sustained and controlled manner.
21 December 2009 - Australia-based biopharmaceutical company Clinuvel Pharmaceuticals Limited (ASX: CUV) today announced promising 4-months results in testing afamelanotide in a multicentre randomised double-blind placebo controlled Phase III study in EPP (CUV017).